A stethoscope resting on a bathroom weighing scale on a tiled floor in soft evening light

Somewhere in a group chat right now, someone is typing: "My cousin's on Mounjaro — her doctor says it's good for the heart too." It's the kind of line that sounds like a bonus you didn't know you were getting.

Mounjaro (tirzepatide) is one of the most talked-about medicines in the world, taken for type 2 diabetes and for weight. So the heart question matters to a lot of people. And in December 2025 we finally got a large trial built to answer it — just not in the way most headlines suggested.

What the trial found

The trial is called SURPASS-CVOT (Nicholls et al., NEJM, 2025). It randomised 13,299 people with type 2 diabetes who also had established cardiovascular disease — narrowed arteries, often a previous heart attack or stroke. These were not people taking the drug for a dress size. Their average age was 64, they'd had diabetes for almost 15 years on average, and 29% were women.

Half received a weekly injection of tirzepatide (up to 15 mg). The other half received dulaglutide (1.5 mg), an older GLP-1 drug that had already been shown to reduce heart attacks and strokes. That's the crucial design choice: there was no placebo. The question wasn't "does tirzepatide protect the heart?" but "is it at least as good as a drug that does?" The trial was double-blind — neither patients nor doctors knew who got which — and funded by Eli Lilly, which makes both drugs.

The result: 12.2% of people on tirzepatide had a cardiovascular death, heart attack or stroke, compared with 13.1% on dulaglutide. In trial language, the hazard ratio was 0.92 — an 8% lower rate — with a confidence interval of 0.83 to 1.01. Because that range brushes against 1.00, the trial met its bar for "non-inferior" (p=0.003) but not for "superior" (p=0.09).

Translated: tirzepatide is at least as good for the heart as a drug we already trust for the heart. It might be a little better. The trial couldn't prove that. Side effects looked similar overall, with more gut problems on tirzepatide.

The wider picture. A 2026 BMJ analysis pooled 262 randomised trials of weight-loss drugs in nearly 100,000 people (Nong et al., BMJ, 2026). Across all of them, injectable semaglutide — Ozempic and Wegovy — was the only drug linked to fewer deaths overall (a risk ratio of 0.81) and fewer heart attacks (0.72), mostly on the strength of large heart trials in high-risk people. Both semaglutide and tirzepatide were linked to roughly half the risk of heart failure (0.43 and 0.49). So tirzepatide has a heart signal. It just doesn't yet have the "fewer heart attacks" badge that semaglutide has earned.

What's still uncertain

Who was studied. Everyone in SURPASS-CVOT had diabetes and existing heart disease. If you take tirzepatide for weight alone, with a healthy heart, this trial didn't study you. Whether it prevents a first heart problem in otherwise healthy people is a different question, and it hasn't been answered.

No placebo. Because the comparison was against an active, heart-protective drug, we can't put a number on tirzepatide versus nothing. The protection is inferred, not measured directly.

"Might be better" is not "is better". A hazard ratio of 0.92 with p=0.09 is a hint. Hints in medicine have a habit of shrinking when re-tested — and sometimes of growing. A second trial, or longer follow-up, would tell.

How the protection works. Weight-loss drugs may help the heart through several routes — weight, blood pressure, blood sugar, the artery wall itself — and which matters most, for which drug, isn't settled. That's why heart failure and heart attack can move differently.

What you'll hear online

"Mounjaro protects your heart." The honest version: in people with diabetes and heart disease, it protected the heart about as well as a drug already proven to do so. It has not been shown to do more than that, and it has not been tested for this in people without diabetes.

What you can do

If you're on tirzepatide — for diabetes or for weight — this trial is reassuring, not a reason to change anything. The things that are proven to protect your heart haven't changed either: blood pressure, cholesterol, not smoking, moving most days. One question worth asking at your next review: "Has my heart risk actually been assessed, and does my current treatment reflect it?" That gets you a personal answer, which a 13,000-person trial never can.

The best news from this trial isn't the headline. It's that we now have two drugs in this class that stand up to a hard test — and that the honest answer, for once, was published alongside the hopeful one.

— Dr. Brugal

The new diabetes treatments — what is real in 2026, and what is coming. · The cardiology procedures your cardiologist may not have had five years ago. · Your blood pressure is talking to your fork. · Managing diabetes every day: what the evidence actually says matters.

References

All studies retrieved via PubMed.

  1. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025;393(24):2409-2420. Double-blind randomised non-inferiority trial, 13,299 people with type 2 diabetes and atherosclerotic cardiovascular disease. doi:10.1056/NEJMoa2505928 (PMID 41406444)
  2. Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;394:e372161. Network meta-analysis of 262 randomised trials, 99,791 people with overweight or obesity, follow-up 12 to 172 weeks. doi:10.1136/bmj-2026-372161 (PMID 42419792)

Awareness content — not medical advice. Always talk to your doctor or pharmacist before making changes.